A new AI-powered interpreter is expected to simulate speakers’ voices in different languages during Microsoft Teams meetings.

The EMA recommended that NUZ-001, formerly monepantel, be granted orphan medicinal product designation to treat ALS in Europe ...

Since its founding, MediciNova has been clear in its mission to deliver new treatment options to the patients suffering with unmet medical needs. In service of that mission, we have been steadfast in ...

Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug ...

The St. Peter’s Hospital ALS Regional Center gives specialized services and resources to people with Amyotrophic Lateral ...

ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord, ultimately leading to muscle weakness and paralysis. ALS is an orphan disease, but its ...

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to ...

Lee Wilson discovered she has a "100%" chance of developing ALS, after losing her father and grandmother to the disease ...

PLL Therapeutics focuses on restoring gut permeability. Its initial indication is Amyotrophic Lateral Sclerosis (ALS), a fatal motor neuron disease. The company’s therapy, PLL001, consists of several ...

Positive results of preclinical studies confirm the potential of Neurizon’s lead drug candidate NUZ-001 to be a ...